Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1644PNH

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:32:28 ON 11 DEC 2009

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   0.22   0.22

FILE 'MEDLINE' ENTERED AT 11:32:51 ON 11 DEC 2009

FILE 'EMBASE' ENTERED AT 11:32:51 ON 11 DEC 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:32:51 ON 11 DEC 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 11:32:51 ON 11 DEC 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:32:51 ON 11 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s drug conjugat?
L1   11194 DRUG CONJUGAT?

=> s l1 and antibod?
L2   3131 L1 AND ANTIBOD?

=> s l2 and fully reducing
L3   0 L2 AND FULLY REDUCING

=> s l2 and reducing agent
L4   19 L2 AND REDUCING AGENT

=> s l4 and reoxidizing
L5   0 L4 AND REOXIDIZING

=> s l4 and oxidizing agent
L6   3 L4 AND OXIDIZING AGENT

=> dup remove l6
PROCESSING COMPLETED FOR L6
L7   3 DUP REMOVE L6 (0 DUPLICATES REMOVED)

=> s l7 and pd<20040302
   1 FILES SEARCHED...
   4 FILES SEARCHED...
L8   0 L7 AND PD<20040302

=> d l7 1-3 cbib abs

L7   ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
2009:487928   Document No. 150:4705290 Cysteine engineered humanized anti-TENB2 **antibodies** and **antibody drug conjugates** for cancer diagnosis and therapy. Mao, Weiguang; Junutula, Jagath Reddy; Polakis, Paul (Genentech, Inc., USA). PCT Int. Appl. WO 2009052249 A1 20090423, 114pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC,

LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-US80102 20081016. PRIORITY: US 2007-981411P 20071019.

AB Cysteine engineered anti-TENB2 **antibodies** are engineered by replacing one or more amino acids of a parent anti-TENB2 **antibody** with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 **antibodies** are provided. Cysteine engineered anti-TENB2 **antibodies** (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 **antibody-drug conjugates** having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered **antibody** drug compds. and compns. are disclosed.

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

2008:1398386 Document No. 149:575039 Cysteine-engineered humanized or chimeric anti-human MUC16 **antibodies** and **antibody drug conjugates** for diagnosis and treatment of cancer. Junutula, Jagath R.; Mallet, William (Genentech, Inc., USA). PCT Int. Appl. WO 2008141044 A2 20081120, 131pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-US62903 20080507. PRIORITY: US 2007-916657P 20070508.

AB Cysteine engineered anti-MUC16 **antibodies** are engineered by replacing one or more amino acids of a parent anti-MUC16 **antibody** with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 **antibodies** are provided. Cysteine engineered anti-MUC16 **antibodies** (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 **antibody-drug conjugates** having Formula I: Ab-(L-D)p where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered **antibody** drug compds. and compns. are disclosed.

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

2007:1390416 Document No. 148:31939 Anti-CD22 **antibodies** and immunoconjugates for diagnosis and treatment of cancer or B cell proliferative disease. Ebens, Allen J., Jr.; Gray, Alane M.; Liang, Wei-Ching; Wu, Yan; Yu, Shang-Fan (Genentech, Inc., USA). PCT Int. Appl. WO 2007140371 A2 20071206, 308 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-US69889 20070529. PRIORITY: US 2006-809328P 20060530; US 2007-908941P 20070329; US 2007-911829P 20070413.

AB Anti-CD22 **antibodies** and immunoconjugates thereof are provided. Methods of using anti-CD22 **antibodies** and immunoconjugates

thereof are provided.

```
=> s conjugate
L9      331860 CONJUGATE

=> s l9 and antibod?
L10      82429 L9 AND ANTIBOD?

=> s l10 and drug
L11      22416 L10 AND DRUG

=> s l11 and reducing agent
L12         74 L11 AND REDUCING AGENT

=> s l12 and DTT
L13          8 L12 AND DTT

=> s l13 and oxidizing agent
L14          0 L13 AND OXIDIZING AGENT

=> s l13 and DTNB
L15          0 L13 AND DTNB

=> s l11 and DTT
L16         35 L11 AND DTT

=> s l16 and DTNB
L17          0 L16 AND DTNB

=> s l16 and cytotoxic agent
L18          0 L16 AND CYTOTOXIC AGENT

=> dup remove l16
PROCESSING COMPLETED FOR L16
L19          22 DUP REMOVE L16 (13 DUPLICATES REMOVED)

=> s l19 and cooling
L20          0 L19 AND COOLING

=> s selective conjugation
L21        151 SELECTIVE CONJUGATION

=> s l21 and fully reducing antibod?
L22          0 L21 AND FULLY REDUCING ANTIBOD?

=> s l21 and reducing agent
L23          0 L21 AND REDUCING AGENT

=> s (alley s?/au or torgov m?/au or sun m?/au)
L24      13588 (ALLEY S?/AU OR TORGOV M?/AU OR SUN M?/AU)

=> s l24 and conjugate
L25        152 L24 AND CONJUGATE

=> s l25 and DTT
L26          5 L25 AND DTT

=> dup remove l26
PROCESSING COMPLETED FOR L26
L27           1 DUP REMOVE L26 (4 DUPLICATES REMOVED)
```

=> d l27 cbib abs

L27 ANSWER 1 OF 1 MEDLINE on STN DUPLICATE 1
2005502081. PubMed ID: 16173809. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. **Sun Michael M C**; Beam Kevin S; Cerveny Charles G; Hamblett Kevin J; Blackmore Richard S; **Torgov Michael Y**; Handley Felicia G M; Ihle Nathan C; Senter Peter D; **Alley Stephen C.** (Seattle Genetics, Inc., 21823 30th Drive SE, Bothell, Washington 98021, USA.) Bioconjugate chemistry, (2005 Sep-Oct) Vol. 16, No. 5, pp. 1282-90. Journal code: 9010319. ISSN: 1043-1802.
Report No.: NLM-NIHMS63637; NLM-PMC2539111. Pub. country: United States.
Language: English.

AB Site-specific conjugation of small molecules and enzymes to monoclonal antibodies has broad utility in the formation of **conjugates** for therapeutic, diagnostic, or structural applications. Precise control over the location of conjugation would yield highly homogeneous materials that could have improved biological properties. We describe for the first time chemical reduction and oxidation methods that lead to preferential cleavage of particular monoclonal antibody interchain disulfides using the anti-CD30 IgG1 monoclonal antibody cAC10. Alkylation of the resulting cAC10 cysteine thiols with the potent antimitotic agent monomethyl auristatin E (MMAE) enabled the assignment of drug conjugation location by purification with hydrophobic interaction chromatography followed by analysis using reversed-phase HPLC and capillary electrophoresis. These analytical methods demonstrated that treating cAC10 with reducing agents such as **DTT** caused preferential reduction of heavy-light chain disulfides, while reoxidation of fully reduced cAC10 interchain disulfides caused preferential reformation of heavy-light chain disulfides. Following MMAE conjugation, the resulting **conjugates** had isomeric homogeneity as high as 60-90%, allowing for control of the distribution of molecular species. The resulting **conjugates** are highly active both in vitro and in vivo and are well tolerated at efficacious doses.

=> s l25 and oxidizing agent
L28 1 L25 AND OXIDIZING AGENT

=> d l28 cbib abs

L28 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
2005:1001873 Document No. 143:304644 Proteins or antibodies conjugated with label or drug for diagnosis and treatment of cancer, immune or autoimmune disease and infection. **Alley, Stephen Charles; Torgov, Michael; Sun, Michael** (Seattle Genetics, Inc., USA). PCT Int. Appl. WO 2005084390 A2 20050915, 98 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2005-US7239 20050302. PRIORITY: US 2004-549476P 20040302.

AB A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radio-metals, chelating agents, and toxins, so as to form a **conjugate** useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.

```
=> s l25 and fully reducing
L29          0 L25 AND FULLY REDUCING

=> s l25 and partially reducing
L30          0 L25 AND PARTIALLY REDUCING

=> s l25 and reducing
L31          7 L25 AND REDUCING

=> s l31 and oxidizing
L32          1 L31 AND OXIDIZING

=> d l32 cbib abs

L32  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
2005:1001873   Document No. 143:304644  Proteins or antibodies conjugated with
     label or drug for diagnosis and treatment of cancer, immune or autoimmune
     disease and infection.  Alley, Stephen Charles; Torgov,
     Michael; Sun, Michael (Seattle Genetics, Inc., USA).  PCT
     Int. Appl. WO 2005084390 A2 20050915, 98 pp.  DESIGNATED STATES: W:  AE,
     AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
     CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU,
     ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
     MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
     SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
     VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
     DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE,
     SN, TD, TG, TR.  (English).  CODEN: PIXXD2.  APPLICATION: WO 2005-US7239
     20050302.  PRIORITY: US 2004-549476P 20040302.
AB   A protein containing one or more activatable groups, e.g., an antibody, is
     subjected to partial or complete reduction of one or more such bonds to form
     reactive groups; the resulting protein is reacted with a drug which is
     reactive with some of the reactive groups, such as certain radio-metals,
     chelating agents, and toxins, so as to form a conjugate useful
     in, e.g., in vitro diagnosis, in vivo imaging, and therapy.


=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   134.03     134.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -4.10      -4.10

STN INTERNATIONAL LOGOFF AT 11:41:37 ON 11 DEC 2009
```